Edition:
India

OPKO Health Inc (OPK.OQ)

OPK.OQ on NASDAQ Stock Exchange Global Select Market

2.41USD
23 Apr 2019
Change (% chg)

-- (--)
Prev Close
$2.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,535,004
52-wk High
$6.39
52-wk Low
$2.29

Latest Key Developments (Source: Significant Developments)

Opko Health Inc Says Topline Analysis Of Results Of Study Demonstrated That OPK88003 Met Primary Objective
Thursday, 21 Mar 2019 

March 21 (Reuters) - OPKO Health Inc ::OPKO ANNOUNCES POSITIVE TOPLINE RESULTS IN PHASE 2 DIABETES AND OBESITY TRIAL.OPKO HEALTH INC - TOPLINE ANALYSIS OF RESULTS OF STUDY DEMONSTRATED THAT OPK88003 MET PRIMARY OBJECTIVE.OPKO HEALTH INC - STUDY ALSO SHOWED STATISTICALLY SIGNIFICANT LOWERING OF HEMOGLOBIN A1C (HBA1C) AFTER 30 WEEKS OF TREATMENT VERSUS PLACEBO.OPKO HEALTH INC - MOST FREQUENT ADVERSE EVENTS WERE NAUSEA, VOMITING AND DIARRHEA IN STUDY.OPKO HEALTH INC - NO SERIOUS ADVERSE EVENTS WERE OBSERVED IN STUDY.  Full Article

Opko Health Inc Announces Proposed Offering Of Convertible Senior Notes
Tuesday, 5 Feb 2019 

Feb 4 (Reuters) - OPKO Health Inc ::OPKO HEALTH INC ANNOUNCES PROPOSED OFFERING OF CONVERTIBLE SENIOR NOTES.OPKO HEALTH INC - INTENDS TO OFFER $200 MILLION AGGREGATE PRINCIPAL AMOUNT OF CONVERTIBLE SENIOR NOTES DUE 2025.OPKO HEALTH INC - NOTES WILL PAY INTEREST SEMIANNUALLY IN ARREARS.OPKO HEALTH INC - INTENDS TO USE NET PROCEEDS RECEIVED FROM OFFERING OF NOTES TO FUND RESEARCH AND DEVELOPMENT.  Full Article

OPKO Health And OPKO's CEO & Chairman, Dr. Phillip Frost, Announce Proposed Resolution Of SEC Action
Friday, 28 Dec 2018 

Dec 27 (Reuters) - OPKO Health Inc ::OPKO HEALTH AND OPKO'S CEO AND CHAIRMAN, DR. PHILLIP FROST, ANNOUNCE PROPOSED RESOLUTION OF SEC ACTION.OPKO HEALTH INC - FROST WILL CONTINUE TO SERVE AS OPKO'S CEO AND CHAIRMAN..OPKO HEALTH INC - FROST TO CONTINUE AS CEO AND CHAIRMAN OF OPKO.OPKO HEALTH INC - FROST AGREED TO INJUNCTIONS FROM CERTAIN VIOLATIONS; ABOUT $5.5 MILLION IN PENALTY, DISGORGEMENT, AND PREJUDGMENT INTEREST.  Full Article

Opko Health Says Board Resolved To Voluntary Delist Common Stock From Tel Aviv Stock Exchange SEC Filing
Tuesday, 10 Apr 2018 

April 9 (Reuters) - OPKO Health Inc ::OPKO HEALTH SAYS BOARD RESOLVED TO VOLUNTARY DELIST COMMON STOCK FROM TEL AVIV STOCK EXCHANGE - SEC FILING.  Full Article

OPKO Health Qtrly Diluted Loss Per Share $0.38
Friday, 2 Mar 2018 

March 1 (Reuters) - OPKO Health Inc ::OPKO HEALTH REPORTS 2017 FOURTH QUARTER BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS.Q4 REVENUE $193.7 MILLION VERSUS $275.5 MILLION.QTRLY DILUTED LOSS PER SHARE $0.38.  Full Article

Opko Health qtrly loss per share $0.08‍​
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Opko Health Inc ::Opko Health reports 2017 third quarter highlights and financial results.Q3 revenue $263.5 million versus I/B/E/S view $319.4 million.Opko Health Inc qtrly loss per share $0.08‍​.  Full Article

OPKO Health submits premarket approval application with FDA for PSA test
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - OPKO Health Inc :OPKO Health submits premarket approval application with FDA for a point-of-care PSA test with the Claros 1 platform.OPKO Health Inc - ‍filing contains clinical data from company's 864-patient total psa clinical study​.OPKO Health Inc - ‍OPKO expects to initiate clinical validation studies and to file a 510(k) application for a Claros 1 testosterone test in 2018​.OPKO Health - working to add additional tests for vitamin D, infectious diseases, cardiology, women's health, companion diagnostics to Claros 1 menu​.  Full Article

Xenetic Biosciences enters into sublicense agreement with subsidiary of Shire Plc
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Xenetic Biosciences :Xenetic Biosciences enters into sublicense agreement related to its Polyxen technology with Baxalta Inc., a wholly-owned subsidiary of Shire Plc.Xenetic Biosciences Inc - ‍Xenetic to receive one-time payment of $7.5 million and single digit royalty payments based upon net sales​.  Full Article

Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Opko Health Inc ::Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy.‍Tesaro is expected to launch Varubi IV in November 2017​.  Full Article

Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee in Japan
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Opko Health Inc :Opko Health enters into exclusive agreement with Japan Tobacco to develop and commercialize Rayaldee® in Japan.Opko Health Inc - ‍Under terms of agreement, JT will make an upfront payment to Opko of $6 million.Opko Health says unit ‍eirgen Pharma entered into an exclusive agreement with Japan Tobacco for development and commercialization in Japan of Rayaldee​.Opko Health - As per agrement, co eligible to receive up to additional $31 million in development & regulatory milestones & $75 million in sales based milestones​.Opko Health Inc - JT will make​ another ‍$6 million payment to co upon initiation of Opko's planned phase 2 study of Rayaldee in U.S. dialysis patients.  Full Article

UPDATE 1-IFR Americas ECM Pipeline

NEW YORK, Feb 5 (IFR) - PRICED Invesco Mortgage Capital (US, mortgage REIT) – $220m Block. 14m shares (100% prim) at $15.73 versus $15.73 fixed-price marketing and $16.30 last sale. MS, CITI, CS. Marcus Corporation (US, movie theaters) – $60.4m Block. 1.5m shares (100% sec) at $40.25 versus $40.25-$40.72 marketing and $40.72 last sale. GS. OPKO Health (US, pharmaceutical) – $200m 6y cvt priced at 4.25%, up 20%. JEFF. CALENDAR Week of Feb 4: Wealthbridge Acquisition (US, SPAC) – $50m IPO. 5m unit